...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in hematology >Advances in the diagnosis and treatment of eosinophilia
【24h】

Advances in the diagnosis and treatment of eosinophilia

机译：嗜酸性粒细胞增多症的诊​​治进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Eosinophils play an important role in the pathogenesis of allergic, infectious and malignant diseases. Over the last decade, new diagnostic tools and treatment modalities have led to the re-evaluation of the existing definition of eosinophilic disorders. This review discusses a recent proposal for new terminology and classification of hypereosinophilia. The results of targeted therapy for hypereosinophilia-related disorders are also summarized. RECENT FINDINGS: A panel of multidisciplinary experts agreed on unifying definitions and criteria of eosinophilia-associated disorders and created a new classification of hypereosinophilia-related conditions based on clinical, haematological and laboratory findings as well as the underlying cause of hypereosinophilia. Recent results of the treatment of idiopathic hypereosinophilic syndrome (HES) with the anti-interleukin 5 monoclonal antibody mepolizumab showed its efficacy and manageable safety profile. The treatment of platelet-derived growth factor alpha (PDGFRA)-positive HES with imatinib demonstrated long-lasting efficacy and low likelihood of drug resistance. SUMMARY: The unifying terminology and definitions should aid physicians caring for patients with hypereosinophilia. Despite much progress, serum biomarkers correlate with disease severity and predict responses to treatment that are needed. There is also a great need for understanding and specific therapy for PDGFRA-negative HES.
机译：审查目的：嗜酸性粒细胞在变应性，传染性和恶性疾病的发病机理中起重要作用。在过去的十年中，新的诊断工具和治疗方式导致对现有嗜酸性粒细胞疾病定义的重新评估。这篇评论讨论了新的术语，关于嗜酸性粒细胞增多症的新术语和分类。还总结了针对嗜酸性粒细胞增多症相关疾病的靶向治疗的结果。最近的发现：一个多学科专家小组一致同意统一嗜酸性粒细胞相关疾病的定义和标准，并根据临床，血液学和实验室检查结果以及嗜酸性粒细胞增多的根本原因，对嗜酸性粒细胞相关病症进行了新的分类。抗白介素5单克隆抗体美泊珠单抗治疗特发性高嗜酸性粒细胞综合征（HES）的最新结果显示了其疗效和可控的安全性。用伊马替尼治疗血小板源性生长因子α（PDGFRA）阳性的HES表现出持久的疗效和低耐药性的可能性。简介：统一的术语和定义应有助于医生照顾嗜酸性粒细胞增多症患者。尽管取得了很大进展，但血清生物标志物仍与疾病严重程度相关，并可以预测对所需治疗的反应。还非常需要PDGFRA阴性HES的理解和特异性疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号